undefined

undefined

Home page

Registration Announcement of Jiudian Hongyang's Pharmaceutical Excipient: Polyacrylic Acid Solution

Registration Announcement of Jiudian Hongyang's Pharmaceutical Excipient: Polyacrylic Acid Solution

Recently, a piece of exciting news has emerged: the polyacrylic acid solution (Registration No.: F20250000498) developed by Jiudian Hongyang as a pharmaceutical excipient has successfully obtained the registration certificate from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China.

25

2025

/

09

Jiudian Pharma Debuts at Egypt's Pharmaconex Exhibition, Its "Going Global" Strategy Recognized by Hunan Medical Products Administration

Jiudian Pharma Debuts at Egypt's Pharmaconex Exhibition, Its "Going Global" Strategy Recognized by Hunan Medical Products Administration

Recently, the International Business Development and Cooperation Team of Jiudian Pharma traveled to Cairo, Egypt, to participate in Pharmaconex, the most influential professional pharmaceutical exhibition in the region. This marked Jiudian Pharma's first appearance in the African and Middle Eastern markets, where it demonstrated its strength and charisma on the international stage, garnering widespread attention and positive feedback.

20

2025

/

09

Hitting a New High! Jiudian Pharma Rises to 76th Place on Hunan Top 100 Manufacturers List

Hitting a New High! Jiudian Pharma Rises to 76th Place on Hunan Top 100 Manufacturers List

On September 16, the list of Hunan Top 100 Manufacturing Enterprises in 2024 was released, with Jiudian Pharmaceutical ranking 76th—an increase of 10 places compared to 2023 and a record high in the company’s history. This breakthrough achievement not only demonstrates the remarkable results of the enterprise’s innovation-driven development and industrial upgrading but also reflects the strong growth momentum of Hunan’s biomedical industry cluster.

18

2025

/

09

Jiudian Pharmaceutical Successfully Passes Joint Inspection by Drug Administrations of Fujian and Hunan Provinces

Jiudian Pharmaceutical Successfully Passes Joint Inspection by Drug Administrations of Fujian and Hunan Provinces

Since the implementation of the new Drug Administration Law, a number of drug marketing authorization holder (MAH, Type B Certificate) enterprises have emerged in China. To further implement the main responsibility of MAHs for quality and strengthen the supervision and management of the entrusted/contract manufacturing links of drugs, the National Medical Products Administration (NMPA) successively issued the Announcement on Strengthening the Supervision and Management of Entrusted Production by Drug Marketing Authorization Holders in October 2023 and the Announcement on Strengthening the Supervision and Management of Contract Manufacturing of Drugs (Draft for Comments) in November 2024.

04

2025

/

09

Joint Training Conducted by Three Workshops of Jiudian Production Center: Consolidating Foundations to Boost Quality and Efficiency

Joint Training Conducted by Three Workshops of Jiudian Production Center: Consolidating Foundations to Boost Quality and Efficiency

On August 27th, to comprehensively enhance employees' overall competence and production efficiency, Workshop 300, Workshop 301, and Workshop 302 of Jiudian Production Center jointly organized an employee training session. The training covered multiple dimensions, including corporate culture, GMP knowledge, quality management, and work safety.

28

2025

/

08

Jiudian Hongyang's API Diacerein Approved for Market Launch

Jiudian Hongyang's API Diacerein Approved for Market Launch

Recently, Jiudian Hongyang’s active pharmaceutical ingredient (API) Diacerein (Y20230001269) achieved a status change to "A" on the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), indicating it has successfully passed evaluation and been approved for market launch.

26

2025

/

08

Jiuyue® Loxoprofen Sodium Gel Patch Wins "SIP Gold Award" Again

Jiuyue® Loxoprofen Sodium Gel Patch Wins "SIP Gold Award" Again

On August 18th, during the 18th China Health Industry Summit (SIP Summit), Sinopharm Healthcare Technology officially released the "2025 Healthy China · Brand List". Relying on its solid brand strength, Jiuyue® Loxoprofen Sodium Gel Patch successfully won the "SIP Gold Award" in the external analgesic category — this is also the second time that the Jiuyue® brand has received this honor following 2024.

20

2025

/

08

Jiudian Pharmaceutical Holds Training on Performance Interviews and Employment Compliance to Enhance Management Efficiency and Risk Prevention

Jiudian Pharmaceutical Holds Training on Performance Interviews and Employment Compliance to Enhance Management Efficiency and Risk Prevention

On the afternoon of August 8th, the Human Resources Department of Jiudian Pharmaceutical organized a special training session on "Performance Interview Skills and Practical Employment Compliance" at the Jiudian Production Center. Focused on the theme of "Enhancing Management Efficiency and Consolidating the Compliance Defense Line", this training invited senior experts such as Dean Wang from the Liuyang Municipal Labor and Personnel Dispute Arbitration Institute to give lectures. More than 50 participants attended the training, including middle-level and above managers from the Jiudian Production Center and all members of the Human Resources Department.

12

2025

/

08

< 1...4 5 6...15 >

Hunan Jiudian

Bldg A1, Wukuang Lugu Science and Technology Industry Park, No.28 Lutian Road, Hi-tech development zone, Changsha, Hunan, China TEL. 0086-731-88220222

1

Business license

Powered by：CEglobal Privacy policy